Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1Chondrosarcoma 1

Interventions

Paclitaxel 35Carboplatin 35Bevacizumab 14olaparib 13niraparib 11apatinib 11Gemcitabine 10liposomal doxorubicin 9Hyperthermic Intraperitoneal Chemotherapy 9Cisplatin 9pembrolizumab 8Cyclophosphamide 8fludarabine 7Etoposide 7Topotecan 6fluzoparib 5Surveys and Questionnaires 5Drug Therapy 5Albumin-Bound Paclitaxel 5anlotinib 4Immunohistochemistry 4Ifosfamide 4Doxorubicin 4Docetaxel 4Cytoreduction Surgical Procedures 4Taxes 3Surgical Procedures, Operative 3Poly(ADP-ribose) Polymerase Inhibitors 3Neoadjuvant Therapy 3Laparoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Ovarian Neoplasms × TQ-B3525 × Clear all
NCT04836663 2021-06-01

A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
90 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡